XML 29 R43.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Disclosure about Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2010
Disclosure about Fair Value of Financial Instruments (Tables) [Abstract]  
Carrying amounts and estimated fair values of financial instruments
                                 
    December 31, 2010     December 31, 2009  
    Carrying     Fair     Carrying     Fair  
    Amount     Value     Amount     Value  
Financial Assets:
                               
 
Mortgage loans receivable
  $ 109,283     $ 111,255     $ 74,517     $ 74,765  
Other real estate loans receivable
    327,297       333,003       352,846       354,429  
Available-for-sale equity investments
    1,103       1,103       5,816       5,816  
Cash and cash equivalents
    131,570       131,570       35,476       35,476  
 
                               
Financial Liabilities:
                               
 
                               
Borrowings under unsecured lines of credit arrangements
  $ 300,000     $ 300,000     $ 140,000     $ 140,000  
Senior unsecured notes
    3,034,949       3,267,638       1,653,027       1,762,129  
Secured debt
    1,125,906       1,178,081       620,995       623,266  
Interest rate swap agreements
    482       482       2,381       2,381  
The Market approach utilized to measure fair value of financial assets and liabilities on recurring basis
                                 
    Fair Value Measurements as of December 31, 2010  
    Total     Level 1     Level 2     Level 3  
Available-for-sale equity investments(1)
  $ 1,103     $ 1,103     $     $  
Assets held for sale(2)
    23,441             23,441        
Interest rate swap agreements(3)
    (482 )           (482 )      
 
                       
 
                             
Totals
  $ 24,062     $ 1,103     $ 22,959     $  
 
                       
 
(1)   Unrealized gains or losses on equity investments are recorded in accumulated other comprehensive income (loss) at each measurement date.
 
(2)   Please see Note 5 for additional information.
 
(3)   Please see Note 11 for additional information.